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Abstract: As the demand for multi-walled carbon nanotube (MWCNT) incorporation into industrial
and biomedical applications increases, so does the potential for unintentional pulmonary MWCNT
exposure, particularly among workers during manufacturing. Pulmonary exposure to MWCNTs
raises the potential for development of lung inflammation, fibrosis, and cancer among those exposed;
however, there are currently no effective biomarkers for detecting lung fibrosis or predicting the risk
of lung cancer resulting from MWCNT exposure. To uncover potential mRNAs and miRNAs that
could be used as markers of exposure, this study compared in vivo mRNA and miRNA expression
in lung tissue and blood of mice exposed to MWCNTs with in vitro mRNA and miRNA expression
from a co-culture model of human lung epithelial and microvascular cells, a system previously
shown to have a higher overall genome-scale correlation with mRNA expression in mouse lungs
than either cell type grown separately. Concordant mRNAs and miRNAs identified by this study
could be used to drive future studies confirming human biomarkers of MWCNT exposure. These
potential biomarkers could be used to assess overall worker health and predict the occurrence of
MWCNT-induced diseases.
Keywords: multi-walled carbon nanotubes; MWCNT; lung fibrosis; biomarkers
1. Introduction
Carbon nanotubes (CNTs) are currently used in diverse industrial and biomedical applications [1–3].
With demand driven mainly by increasing applications in manufacturing and decreasing costs of
production, the estimated global market value of CNTs is USD 9.85 billion by 2023 [1]. CNT production
leads to potential particle exposure in occupational, consumer, and environmental settings, with the
highest incidence of unintentional CNT exposure occurring in occupational settings [3]. Particle and
dust generation during CNT manufacturing may lead to inhalation exposure to CNTs when these
particles become airborne and enter the breathing zone [3,4].
Inhalation of CNTs, particularly multi-walled CNTs (MWCNTs), concentric tubes of rolled
graphene, poses a health risk due to their long, rigid, needle-like structure [3]. In humans, workers
exposed to MWCNTs during manufacturing were found to have increased reactive oxygen species
in exhaled breath condensate as well as elevated profibrotic inflammatory mediators in sputum and
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serum samples compared with non-exposed workers [4]. Numerous animal studies monitoring the
effects of MWCNTs delivered by either intratracheal instillation or inhalation have found increased
levels of DNA damage and neutrophil influx following MWCNT exposure [5]. In vitro, exposure of
cells found within the pulmonary space, such as alveolar epithelial cells, fibroblasts, and macrophages,
to MWCNTs also produces results, such as increases in inflammatory markers, supportive of the
toxicity of MWCNT exposure [6,7].
MWCNTs delivered to mice by pharyngeal aspiration deposited in the alveolar region of the lungs
and translocated to the subpleural space starting one day after exposure [8]. While this may be a normal
clearance mechanism for small particles, longer fibers may not be able to properly migrate through the
subpleural space [3,9]. Approximately 65% of the original MWCNT burden remained in the lungs
up to 336 days post-exposure; this retention may lead to inflammation and pulmonary fibrosis [3].
While fibrosis is a normal regenerative process following lung injury, insoluble materials that impair
the clearance process and lead to a prolonged inflammatory response may result in pulmonary fibrosis,
limiting the diffusion capacity for oxygen and resulting in loss of pulmonary function [10]. Additionally,
MWCNTs have been categorized by the International Agency for Research on Cancer as group 2B,
possibly carcinogenic to humans [11].
While our group has previously found that MWCNT exposure is related to a subset of lung
cancer biomarkers in mice following short-term exposure, there are currently no effective biomarkers
derived from long-term exposures that are able to detect human lung fibrosis or predict the risk of
subsequent lung cancer [12]. Previous studies have shown that animal model-based gene expression
profiling can successfully predict human target organ toxicities for numerous human diseases, including
cancer [13–16]. Using in vivo mRNA and miRNA data derived from a study of mice exposed to
MWCNT and sacrificed at 1, 6, and 12 months post-exposure [17] and in vitro mRNA and miRNA
data derived from a coculture model of human small airway epithelial cells (SAEC) and human
microvascular endothelial cells (HMVEC) exposed to MWCNT for 6 and 24 h [18], this study identified
mRNAs with concordant MWCNT-induced expression perturbation in in vivo and in vitro studies,
identifying them as potential biomarkers for medical and occupational surveillance in humans.
The concordant biomarkers identified from this study could be readily tested in human blood samples
for monitoring MWCNT-induced disease risk in future studies.
2. Results
2.1. mRNAs Concordant Between Mouse Tissue and Human Cells
A total of 55 unique mRNAs were identified in mouse lung tissue and SAEC and HMVEC that
were concordant regarding changes in gene expression. Table 1 lists the name, expression change
direction, and function of the 44 concordant mRNAs between mouse lung tissues at 1, 6, and 12
months post-exposure and SAEC at 6 and 24 h time points. Of these 44 concordant mRNAs, four were
upregulated and 40 were downregulated. The fold change values and disease implications for each gene
are summarized in Supplemental File 1.
Table 1. Concordant mRNAs in mouse tissue and human small airway epithelial cells (SAEC).
mRNA Tissue and Cell Regulation Function
1-month animal exposure
CAND1 Downregulated Ubiquitin ligase regulation
CYCS Downregulated Electron transport chain in mitochondria
DENND5B Downregulated Calcium ion transmembrane transport
HS3ST3B1 Downregulated Sulfotransferase
MAML1 Downregulated Cell fate determination
MAN2B2 Downregulated Hydrolase
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Table 1. Cont.
mRNA Tissue and Cell Regulation Function
1-month animal exposure
METTL21 Downregulated Methyltransferase
PIGS Downregulated GPI-anchor biosynthesis
PPP1C Downregulated Phosphatase
S100A5 Upregulated Calcium binding
SEL1L Downregulated Misfolded protein translocation
SH3BP2 Downregulated Adaptor protein
SLC7A1 Downregulated Transmembrane transporter
TGM2 Downregulated Transglutaminase
XRN2 Downregulated Exonuclease
6-month animal exposure
KIF14 Downregulated Microtubule motor protein
MYBPC2 Upregulated Myosin binding
PSD4 Upregulated ARF protein signal transduction
TTLL7 Downregulated Cell differentiation
12-month animal exposure
ADH5 Downregulated Alcohol dehydrogenase
ANLN Downregulated Cell growth and migration
ARF1 Downregulated Guanine nucleotide binding
CCDC115 Downregulated Unfolded protein binding
CYCS Downregulated Electron transport chain in mitochondria
DDX24 Downregulated RNA helicase
FAM188A Downregulated Apoptosis
IKZF2 Downregulated Zinc finger protein
IL1R1 Downregulated Interleukin receptor
INTS4 Downregulated snRNA processing
MAD2L1 Downregulated Mitotic spindle assembly checkpoint
PIGU Downregulated Cell division control
PIKFYVE Downregulated Cytoskeletal functions, membrane trafficking, and receptor signaling
PNRC2 Downregulated DNA/mRNA binding
PRKRIR Downregulated Regulation of cell proliferation
PRIM2 Downregulated Replication of DNA
RNF19A Downregulated Ubiquitin ligase
SDHD Downregulated Succinate oxidation
SGOL2 Downregulated Cell cycle regulation
SLC30A7 Downregulated Zinc transporter
TMPO Downregulated Nuclear organization
TMPRSS6 Upregulated Serine proteinase
UBE2E1 Downregulated Ubiquitination
VAC14 Downregulated Regulates levels of phosphatidylinositol 3,5-bisphosphate
WDR74 Downregulated RNA regulation
Table 2 lists the name, expression direction, and function of the 24 concordant mRNAs between
mouse lung tissue at 1 month, 6 months, and 12 months and HMVEC at any time point. Of these 24
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concordant mRNAs, four were upregulated and 20 were downregulated. The fold change values and
disease implications for each gene are summarized in Supplemental File 1.
Table 2. Concordant mRNAs in mouse tissue and human microvascular endothelial cells (HMVEC).
mRNA Tissue and Cell Regulation Function
1-month animal exposure
CAND1 Downregulated Ubiquitin ligase regulation
HIST1H3F Upregulated DNA structure
PPP1CC Downregulated Phosphatase
SH2D1A Downregulated T and B cell stimulation
SH3BP2 Downregulated Adaptor protein
SLC22A5 Downregulated Glucose transporter
TGM2 Downregulated Transglutaminase
6-month animal exposure
HIST1H2AL Upregulated DNA structure
TFEC Downregulated Transcription factor
12-month animal exposure
ABCE1 Downregulated Molecular transport
EIF4B Downregulated Helicase
IKZF2 Downregulated Transcription factor
IL1R1 Downregulated Interleukin receptor
LXN Downregulated Metallocarboxypeptidase inhibition
MID1 Upregulated Adaptor protein
NPM1 Downregulated ARF/p53 regulation
NUDT8 Upregulated Hydrolase
PIKFYVE Downregulated Cytoskeletal functions, membranetrafficking, and receptor signaling
PPP1CC Downregulated Phosphatase
SDHD Downregulated Succinate oxidation
SLC30A7 Downregulated Zinc transporter
SMARCAD1 Downregulated Helicase
UBE2E1 Downregulated Ubiquitination
ZC3H13 Downregulated mRNA methylation
2.2. mRNAs Concordant Between Mouse Blood and Human Cells
A total of 15 unique mRNAs were identified in mouse blood and SAEC and HMVEC that were
concordant regarding changes in gene expression. Table 3 lists the name, expression direction, and
function of the eight concordant mRNAs between mouse blood at 1 month, 6 months, and 12 months
and SAEC at any time point. Of these eight concordant mRNAs, one was upregulated and seven were
downregulated. The fold change values and disease implications for each gene are summarized in
Supplemental File 1.
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Table 3. Concordant mRNAs in mouse blood and SAEC.
mRNA Blood and Cell Regulation Function
1-month animal exposure
CFTR Downregulated Multidrug resistance
HSD17B2 Upregulated Bone development
PER1 Downregulated Circadian rhythm
RIMKLB Downregulated Amino acid synthesis
SH3RF3 Downregulated Metal ion binding
SLC7A1 Downregulated Amino acid transport
6-month animal exposure
HMGB2 Downregulated DNA bending
12-month animal exposure
SYTL3 Downregulated Vesicle trafficking
Table 4 lists the name, expression direction, and function of the eight concordant mRNAs between
mouse blood at 1 month and 6 months and HMVEC at any time point. There were no concordant
mRNAs between HMVEC and mouse blood at 12 months. Of these eight concordant mRNAs, five were
upregulated and three were downregulated. The fold change values and disease implications for each
gene are summarized in Supplemental File 1.
Table 4. Concordant mRNAs in mouse blood and HMVEC.
mRNA Blood and Cell Regulation Function
1-month animal exposure
PER1 Downregulated Circadian rhythm
SLC22A5 Downregulated Glucose transporter
TUBA1B Upregulated Cell division
6-month animal exposure
HIST1H3H Upregulated Chromosomal structure
KPRP Upregulated Keratinocyte differentiation
KRT79 Upregulated Epithelial cell integrity
MID1 Downregulated Adaptor protein
SHCBP1 Upregulated Cell proliferation
2.3. mRNAs Concordant between Mouse Lung Tissue, Mouse Blood, and Human Cells
Two mRNAs were found to have concordant expression between mouse lung tissue, mouse
blood, and in vitro expression: SLC7A1 and SLC22A5. SLC7A1, solute carrier family 7 member 1,
encodes a protein integral to the plasma membrane that is responsible for transport of amino acids
across the plasma membrane and is involved in nitric oxide signaling. SLC7A1 was downregulated
following MWCNT exposure. SLC22A5, solute carrier family 22 member 5, encodes a protein integral
to the plasma membrane that is responsible for organic cation and carnitine transport. SLC22A5 was
downregulated following MWCNT exposure.
2.4. miRNAs Concordant Between Mouse Tissue and Human Cells
A total of four unique miRNAs were identified in mouse lung tissue and SAEC and HMVEC that
were concordant regarding changes in gene expression. Table 5 lists the name of these four concordant
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miRNAs between mouse lung tissues at 1 month, 6 months, and 12 months and SAEC and HMVEC at
any time point. Of these four concordant miRNAs, all were upregulated.
Table 5. Concordant miRNAs in mouse tissue and SAEC or HMVEC.
1-Month Animal Exposure 6-Month Animal Exposure 12-Month Animal Exposure
SAEC
miR-183 miR-204 miR-335
HMVEC
None miR-204 miR-335; miR-26b
2.5. miRNAs Concordant between Mouse Blood and Human Cells
A total of two unique miRNAs were identified in mouse blood and SAEC and HMVEC that were
concordant regarding changes in gene expression. Table 6 lists the name of the two concordant miRNAs
between mouse blood at 1 month and SAEC or HMVEC. There were no concordant miRNAs between
mouse blood at 6 and 12 months postexposure and in vitro expression. All miRNAs were upregulated.
Table 6. Concordant miRNAs in mouse blood and SAEC.
1-Month Animal Exposure 6-Month Animal Exposure 12-Month Animal Exposure
SAEC
miR-148b None None
HMVEC
miR-29c None None
2.6. IPA Analysis of Tissue and Cell Concordant mRNAs and miRNAs
All mRNAs and miRNAs concordant between mouse lung tissue and SAEC or HMVEC at
any time point were input into Ingenuity Pathway Analysis® (IPA; QIAGEN Inc., https://www.
qiagenbioinformatics.com/products/ingenuitypathway-analysis) for analysis of potential cell signaling
involvement. The top five molecular and cellular functions associated with the concordant mRNAs
are summarized in Figure 1A, while the top five associated diseases and disorders are summarized
in Figure 1B. Additionally, these mRNAs were also analyzed for their involvement in diseases and
functions previously reported to be related to MWNCT exposure [19]. Several mRNAs listed in Tables 1
and 2 were found to be associated with fibrosis, inflammatory response, adhesion of neutrophils, and
hypertension (Figure 1C); mRNAs that were not currently found to be involved in these processes were
removed. To determine potential signaling regulation between tissue and cell concordant mRNAs
and miRNAs, all mRNAs and miRNAs concordant between mouse lung tissue and SAEC or HMVEC
at any time point were input into IPA and analyzed for potential connections, which are shown in
Figure 1D.
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2.7. IPA Analysis of Blood and Cell Concordant mRNAs
All mRNAs concordant between mouse blood and SAEC or HMVEC at any time point were
input into IPA for analysis of potential cell signaling involvement. The top five molecular and
cellular functions associated with these concordant mRNAs are shown in Figure 2A, while the top
five associated diseases and disorders are summarized in Figure 2B. The relationship between the
mRNAs listed in Tables 3 and 4 with known MWCNT-related diseases and functions are summarized
in Figure 2C; mRNAs that were not currently found to be involved in these processes were removed.
No mRNAs were found to be involved in adhesion of neutrophils or hypertension. To determine
potential signaling regulation between blood and cell concordant mRNAs and miRNAs, all mRNAs
and miRNAs concordant between mouse blood and SAEC or HMVEC at any time point were input
into IPA and analyzed for potential connections. These potential regulatory connections are shown in
Figure 2D.
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW  7 of 16 
 
All mRNAs concordant between mouse blood and SAEC or HMVEC at any time point were input into 
IPA  for  analysis of potential  cell  signaling  involvement. The  top  five molecular  and  cellular  functions 
associated with these concordant mRNAs are shown in Figure 2A, while the top five associated diseases 
and disorders are summarized in Figure 2B. The relationship between the mRNAs listed in Table 3 and 
Table 4 with known MWCNT‐related diseases and functions are summarized in Figure 2C; mRNAs that 
were not currently found to be involved in these processes were removed. No mRNAs were found to be 
involved in adhesion of neutrophils or hypertension. To determine potential signaling regulation between 
bloo  and cell concordant mRNAs and miRNAs, all mRNAs and miRNAs concordant bet een mo se 
blood and SAEC or HMVEC at a y time point were input into IPA and analyzed for pote ti l connectio s. 
These potential regulatory connections are shown in Figure 2D. 
 
Figure 2. Blood and Cell Concordant mRNA and miRNA IPA Analysis. (A) Top five molecular and cellular 
functions  associated  with  concordant  mRNAs.  (B)  Top  five  diseases  and  disorders  associated  with 
concordant mRNAs.  (C) mRNAs  associated with known MWCNT  exposure outcomes.  (D) mRNA and 
miRNA regulation in blood and cell concordant mRNAs and miRNAs. 
3. Discussion 
This  study  identified  mRNAs  and  miRNAs  with  concordant  MWCNT‐induced  expression 
perturbation between in vivo and in vitro settings. We previously reported that MWCNT‐induced mRNA 
expression  in SAEC and HMVEC grown  in co‐culture has higher overall genome‐scale correlation with 
mRNA expression in mouse lungs following MWCNT inhalation than either cell type grown separately in 
culture [18]; therefore, the mRNAs and miRNAs identified in this study may serve as potential biomarkers 
for medical and occupational surveillance in humans in future studies. 
Overall,  tissue  and  cell  concordant mRNAs  as well  as  the blood  and  cell  concordant mRNAs  are 
involved in many cellular processes and have varied disease implications. Two mRNAs were concordant 
between  all  tissue,  blood,  and  cell  analyses:  SLC7A1  and  SLC22A5,  both  of which were  found  to  be 
downregulated following MWCNT exposure. 
The SLC7A1 gene encodes the CAT‐1 protein, a transmembrane protein involved in the transport of 
amino acids, particularly arginine; CAT‐1 is part of the nitric oxide signaling pathway [20]. CAT‐1 plays an 
important role in the influx of L‐arginine, a substrate necessary for proper eNOS function. When SLC7A1 
functionality, and thus arginine transport, is lost, nitric oxide production can become abnormal, potentially 
resulting  in  certain  vascular  disorders,  such  as  hypertension  [20].  In  a  study  by  Chen  et  al.  (2015), 
instillation of MWCNTs into rats resulted in an increase of markers indicative of numerous cardiovascular 
diseases, including hypertension [21]. Chen et al. (2015) noted that this effect was particularly noticeable in 
Figure 2. Blood and Cell C ncordant mRNA and miRN IPA Analysis. (A) Top fiv molecular and
cellular functions associated with concordant mRNAs. (B) Top five dise ses and disorder associated
with co cordant mRNAs. (C) mRNAs ssociated with k own MWCNT exposure outcomes. (D) mRNA
and miRNA regulation in blood and cell co cordant mRNAs and miRNAs.
Int. J. Mol. Sci. 2019, 20, 2635 8 of 15
3. Discussion
This study identified mRNAs and miRNAs with concordant MWCNT-induced expression
perturbation between in vivo and in vitro settings. We previously reported that MWCNT-induced
mRNA expression in SAEC and HMVEC grown in co-culture has higher overall genome-scale
correlation with mRNA expression in mouse lungs following MWCNT inhalation than either cell type
grown separately in culture [18]; therefore, the mRNAs and miRNAs identified in this study may serve
as potential biomarkers for medical and occupational surveillance in humans in future studies.
Overall, tissue and cell concordant mRNAs as well as the blood and cell concordant mRNAs
are involved in many cellular processes and have varied disease implications. Two mRNAs were
concordant between all tissue, blood, and cell analyses: SLC7A1 and SLC22A5, both of which were
found to be downregulated following MWCNT exposure.
The SLC7A1 gene encodes the CAT-1 protein, a transmembrane protein involved in the transport of
amino acids, particularly arginine; CAT-1 is part of the nitric oxide signaling pathway [20]. CAT-1 plays an
important role in the influx of L-arginine, a substrate necessary for proper eNOS function. When SLC7A1
functionality, and thus arginine transport, is lost, nitric oxide production can become abnormal, potentially
resulting in certain vascular disorders, such as hypertension [20]. In a study by Chen et al. (2015),
instillation of MWCNTs into rats resulted in an increase of markers indicative of numerous cardiovascular
diseases, including hypertension [21]. Chen et al. (2015) noted that this effect was particularly noticeable in
spontaneously hypertensive rats, which are considered a good model of human primary hypertension [21].
Several in vivo studies have also shown that pulmonary exposure to MWCNTs induces impairment
of arteriolar dilation, vascular dysfunction, and cardiac ischemia/reperfusion injury [22–25], and a
human population study showed an association between workers exposed to MWCNTs and ICAM-1,
a cardiovascular biomarker [26]. Recently, a study demonstrated that inhalation of MWCNTs significantly
increased both systolic and diastolic blood pressure and decreased heart rate in rats [27]. Coupled together,
these results and our outcomes suggest that mRNA expression levels of SLC7A1 may serve as both a
tissue and blood biomarker of hypertension in workers exposed to MWCNTs and may be particularly
useful in workers with preexisting cardiovascular disease.
The SLC22A5 gene encodes the OCTN2 protein, an integral membrane protein that functions as
both an organic cation transporter and a sodium-dependent carnitine transporter. Downregulation
of SLC22A5 can induce primary carnitine deficiency, which is characterized by encephalopathy,
cardiomyopathy, cardiomegaly, metabolic derangement, hypoglycemia, and muscle weakness [28,29].
Reduced OCTN2 levels have also been noted in cellular studies of cancer, while OCTN2 knockout mice
have systemic immune activation and inflammation [29,30]. Like SLC7A1, tissue and blood expression
levels of SLC22A5 may indicate a MWCNT-induced disease state and can potentially be used as a
biomarker of disease.
IPA analysis of mRNAs concordant between cell and mouse lung tissue analyses identified their top
five related molecular and cellular functions to be cellular assembly and organization; DNA replication,
recombination, and repair; carbohydrate metabolism, lipid metabolism, and small molecule biochemistry.
Examining these functions in more detail, MWCNT exposure caused perturbation of genes involved
in chromosomal aggregation, catabolism of DNA, and phosphatidylinositol 3,5-diphosphate synthesis.
Cellular exposure to MWCNT at occupationally relevant doses has been shown to disrupt mitosis and
result in polyploidy and other genetic damage [31]. IPA analysis also identified the top five diseases and
disorders associated with cell and lung tissue concordant mRNA to be hematological disease, cancer,
gastrointestinal disease, hepatic system disease, and organismal injury and abnormalities. The effects of
these mRNAs on these diseases and disorders also suggest potential MWCNT-induced chromosome
and DNA damage, which is consistent with previously reported genotoxicity and carcinogenicity of
MWCNTs [31,32]. A study demonstrated that MWCNTs promote growth and neoplastic progression
of initiated lung cells in mice following inhalation exposure [33]. Moreover, inhalation of MWCNTs
significantly increased lung carcinomas and combined carcinoma and adenoma formation in mice in a
104-week carcinogenicity study [32].
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Of the tissue and cell concordant mRNAs, CAND1 was found to be associated with hypertension,
while IL1R1 was found to be associated with adhesion of neutrophils and fibrosis and IL1R1 in
conjunction with TGM2 was associated with an overall inflammatory response, all of which are
outcomes attributed to MWCNT exposure. When incorporating both cell and tissue concordant
mRNAs and miRNAs, miRNA/mRNA interactions were found between miR-183 and SEL1L and
SLC30A7; miR-26b and MAN2B2; and miR-204 and NPM1. MiR-183, miR-26b, and miR-204 have all
been implicated in the progression of cancer, and their expression and subsequent effects on signaling
pathways may serve as miRNA biomarkers of MWCNT exposure and potential disease [34–36].
IPA analysis of mRNAs concordant between cell and mouse blood analyses identified their top
five related molecular and cellular functions to be lipid metabolism, small molecule biochemistry,
vitamin and mineral metabolism, amino acid metabolism, and cell morphology. When looking at
these functions in more detail, MWCNT exposure caused perturbation of genes involved in cellular
metabolism and cellular morphology, particularly overall cell size and the size of the centrosome.
As suggested with the cell and tissue concordant mRNA molecular and cellular functions, perturbations
in mRNA expression in blood following MWCNT exposure may suggest DNA damage and overall
loss of cellular integrity. IPA analysis also identified the top five diseases and disorders associated with
cell and lung tissue concordant mRNA to be developmental disorder, hereditary disorder, metabolic
disorder, organismal injury and abnormalities, and respiratory disease. When considered together,
aberrant mRNA expression in these categories was associated with cystic fibrosis, suggesting that
these mRNAs can be surveyed in blood and potentially act as biomarkers of lung fibrosis.
Of the cell and blood concordant mRNAs, CFTR was found to be associated with fibrosis and an
inflammatory response, while potential miRNA/mRNA regulation was found between miR-148a-3p
and SCL22A5. As with the regulatory pathways from the cell and tissue concordant analysis, these
mRNAs and miRNAs and their potential signaling pathways may serve as blood biomarkers of
MWCNT exposure and disease.
There are currently no effective biomarkers to detect human lung fibrosis or predict the risk
of subsequent lung cancer resulting from MWCNT exposure. The mRNAs and miRNAs and their
potential signaling pathways identified in this study from both mouse lung tissue and blood could
possibly be used in future studies to confirm biomarkers of MWCNT exposure in the workplace. These
biomarkers could not only be used to assess overall worker health but also predict the occurrence of
MWCNT-induced disease.
4. Materials and Methods
4.1. MWCNT
The MWCNT used in this study has been previously described [17]. Briefly, the MWCNT were
obtained from Mitsui & Company (MWNT-7, lot #05072001K28) and manufactured using a floating
reactant catalytic chemical vapor deposition method followed by high-temperature thermal treatment
in argon at 2500 ◦C using a continuous furnace [37]. Extensive characterization of the MWCNT was
previously published in Reference [38]. In summary, the number of walls ranged between 20 and 50,
median length was 3.86 ± 1.9 µm, and count mean width was 49 ± 13.4 nm. Trace metal contamination
was 0.78%, with sodium (Na, 0.41%) and iron (Fe, 0.32%) being the two major metal contaminants [38].
Endotoxin levels in the MWCNT were below the levels of detection [38].
4.2. In Vivo Studies
The animal study from which the in vivo data for this study was derived has been previously
reported in Reference [17]. Briefly, Male C57BL/J6 mice (7 weeks old, average weight 21.19 g ± 0.06 g)
were obtained from Jackson Laboratories (Bar Harbor, ME). The study consisted of three components:
bronchoalveolar lavage (BAL), pulmonary histopathology, and lung tissue mRNA microarray analysis.
Each component consisted of eight mice per exposure group (dispersion media [DM, negative control];
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1, 10, 40, or 80 µg MWCNT; 120 µg crocidolite asbestos [positive control]) to be sacrificed at 1, 6 or
12 months post-exposure, for a total of 144 mice per each arm of BAL, pulmonary histopathology,
and lung tissue mRNA microarray analysis and 432 mice for the total study. Rationale for the dose
selection of MWCNT has been previously described in Reference [38].
4.3. In Vivo mRNA Microarray Processing
Global mRNA expression profiles were generated with Mouse Gene ST 2.1 plates at the University
of Michigan Microarray Facility using an Affymetrix Plus kit. cDNA was synthesized from 500 ng total
RNA, amplified, fragmented, and biotinylated using a GeneChip WT PLUS Reagent kit (Affymetrix;
Santa Clara, CA, USA) according to manufacturer’s instructions. cDNA was then prepared for
hybridization with reagents from the Affymetrix GeneTitan Hybridization, Wash, and Stain Kit for WT
Array Plates. For hybridization, 2.76 µg labeled cDNA were hybridized to the Affymetrix Mouse Gene
ST 2.1 Arrays, which were then washed, stained, and scanned using the GeneTitan Multi-Channel
Instrument according to Affymetrix’s User Guide for Expression Array Plates (P/N 702933 Rev. 2, 2013).
Data were analyzed using the Limma, Oligo, and Affy Bioconductor packages implemented in the R
statistical environment. The robust multi-array average was used to normalize the data and fit log2
transformed expression values. The raw microarray data were processed using a robust multi-array
average method, and expression values were log2 transformed, with a principal component analysis
utilized as the final quality control step to visualize mRNA expression values [39]. The analysis
was performed with the oligo package of Bioconductor in the R statistical environment. The mRNA
expression profiles in mouse blood are available in NCBI Gene Expression Omnibus (GEO) with the
accession number GSE126959.
4.4. In Vitro Studies
The cellular study from which the in vitro data for this investigation was derived has been
previously described in Reference [18]. Briefly, for monoculture exposures, SAEC and HMVEC were
plated directly into 100 mm cell culture dishes (Corning, Tewksbury, MA, USA; growth area: 55 cm2),
allowed to form intact barriers for 72 h, serum starved overnight, and exposed directly to MWCNT
at a concentration of 1.2 µg/mL in 10 mL of their respective media for either 6 or 24 h. DM for 24 h
was used as a negative control. For co-culture exposures, SAEC were seeded onto apical transwell
chambers while HMVEC were planted into the basolateral chambers of a 6-well transwell dish. SAEC
and HMVEC were allowed to form intact epithelial and endothelial barriers for 72 h, serum starved
overnight, and SAEC were exposed to MWCNT at a concentration of 1.2 µg/mL in 10 mL of SAEC
media for either 6 or 24 h. DM for 24 h was used as a negative control. HMVEC in the coculture
system were not directly exposed to MWCNT, and MWCNT are not apparent in HMVEC transmission
electron microscopy preparations following SAEC exposure in co-culture.
4.5. In Vitro Microarray mRNA Profiling
RNA samples were analyzed for expression profiling using Agilent G3 Human Gene Expression
8 × 60 k Arrays (Agilent; Santa Clara, CA, USA). Total RNA quality for both microarray analyses
was determined on an Agilent 2100 Bioanalyzer, with all samples having RNA integrity numbers
greater than 8. Total RNA (250 ng) was used for labeling using a QuickAmp labeling kit (Agilent).
Extracted RNA was labeled with cyanine (Cy)-3-CTP (PerkinElmer; Waltham, MA, USA) and reference
RNA with (Cy)-5-CTP. Following purification of labeled cRNAs, 825 ng of Cy3- and Cy5-labeled
cRNAs were combined and hybridized for 17 h at 65 ◦C in an Agilent hybridization oven. Microarrays
were then washed and scanned using an Agilent DNA Microarray Scanner. The mRNA expression
profiles in SAEC and HMVEC couture and monoculture are available in NCBI GEO with the accession
number GSE129640.
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4.6. miRNA Expression Profiling and Processing
For in vivo animal blood miRNA profiling, RNA samples were sent to Ocean Ridge Biosciences
(Palm Beach Gardens, FL, USA) for analysis using custom, multi-species microarrays containing 10,290
total features present in miRBase version 19. For in vitro cell studies, total RNA was analyzed using
custom, multi-species microarrays containing 8817 human miRNA total features present in miRBase
version 17 by Ocean Ridge Biosciences (Palm Beach Gardens, FL, USA). The sensitivity of the microarray
is such that it could detect as low as 20 moles of synthetic miRNA being hybridized along with each
sample. The microarrays were produced by Microarrays Inc. (Huntsville, Alabama) and consisted of
epoxide glass substrates that had been spotted in triplicate with each probe. Quality control of the total
RNA samples was assessed using UV spectrophotometry and agarose gel electrophoresis. The samples
were DNAse digested, and low-molecular weight (LMW) RNA was isolated by ultrafiltration through
YM-100 columns (Millipore; St Louis, MO, USA) and subsequently purified using a RNeasy MinElute
Clean-Up Kit (Qiagen; Germantown, MD, USA). The LMW RNA samples were 3′-end labeled with
Oyster-550 fluorescent dye using a Flash Taq RNA Labeling Kit (Genisphere; Hatfield, PA, USA).
Labeled LMW RNA samples were hybridized to the miRNA microarrays according to conditions
recommended in the Flash Taq RNA Labeling Kit manual. The microarrays were scanned on an Axon
Genepix 4000B scanner, and data were extracted from images using GenePix V4.1 software.
Spot intensities were obtained for all the features on each microarray by subtracting the median
local background from the median local foreground for each spot. Detection Thresholds (T) for each
array were determined by calculating the 10% trim mean intensity of the negative control spots and
adding 5× the standard deviation of the background (non-spot area). The spot intensities and the
T were transformed by taking the log2 base 2 of each value. The normalization factor (N) for each
microarray was determined by obtaining the 20% trim mean of the spot intensities for the mouse
probes above threshold in all samples. The log2-transformed spot intensities for all the features were
normalized by subtracting N from each spot intensity and scaled by adding the grand mean of N
across all microarrays. The mean probe intensities for each of the 1936 mouse probes on each of the
160 arrays (one sample per array) were then determined by averaging the triplicate spot intensities.
Spots flagged as poor quality during data extraction were omitted prior to averaging. The 704 mouse
non-control, log2-transformed, normalized, and averaged probe processing intensities were filtered to
obtain a list of 484 mouse miRNA probes showing probe intensity above T in all samples from at least
one treatment group.
After quality control and preprocessing, 385 detectable mouse miRNA probes from the in vivo
studies, and 555 human miRNA probes in HMVEC and 543 human miRNA probes in SAEC from the
in vitro studies, were detected for further analysis. The miRNA expression profiles are available in the
NCBI GEO database with accession numbers GSE130109 (mouse blood miRNA), GSE130790 (mouse
lung miRNA), and GSE13123 (cellular miRNA).
4.7. In Vivo mRNA/miRNA Microarray Data Analysis
The mouse mRNA microarray consisted of 41,345 probes. Variance was calculated for each probe
across all samples to remove any probe with variance >0.2. All probes resulted in variance <0.2;
therefore, no probes were removed due to variance. Unknowns were then removed from the data,
leaving 25,616 probes. Data analysis was performed with 26,191 probes. ANOVA was used to compare
each treatment group at each post-exposure time point to its respective DM control to determine
significantly up- and down-regulated mRNAs with a p-value <0.05, false discovery rate (FDR) of 10%,
and fold change (FC) ≥1.5. Similar analysis was applied to miRNA microarray data analysis.
4.8. In Vitro mRNA/miRNA Microarray Data Analysis
In vitro microarray data were exported using Feature Extraction v10 as tab-delimited text files
after background subtraction, log2 transformation, and lowess normalization and reported as log or
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relative expression of sample compared to a universal reference. Data were read from each file into R
using a custom script [40]. For each array, values for control spots, spots that were saturated on either
channel, spots that were reported by Feature Extraction as non-uniform outliers on either channel,
and spots which were not well above background on at least one channel were considered unreliable
and/or uninformative and replaced by “NA.” Values were collated into a single table, and probes for
which fewer than ten present values were available were removed. For probes spotted multiple times
on the array, values were averaged across replicate probes.
Missing data were imputed using the K-means nearest neighbor algorithm as implemented by the
impute.knn function in the impute R package from Bioconductor (Bioconductor; Seattle, WA, USA).
For each dose and time point, a set of differentially expressed genes was identified by performing a
two-class unpaired Significance Analysis of Microarrays (SAM) between the treated samples and the
dose zero samples from the corresponding time point, using the Bioconductor package. A threshold
delta value was chosen to produce a false discovery rate of 10% using the findDelta function from the
same package. The list of probes called as significant were subsequently filtered by restricting to those
probes which were at least 1.5-fold up- or down-regulated (fold changes were computed from the data
before imputation of missing values).
4.9. Identification of Concordant Genes from In Vitro and In Vivo Studies
The mouse and human genomes were matched by gene name using the data mining tool Biomart
based on Ensembl Genes version 68 (http://www.ensembl.org/biomart/martview/) [41]. There was a
total of 15,473 matched genes (orthologs) between human and mouse. For ortholog genes defined as a
“one-to-many” or “many-to-many” relationship between the mouse and human genome, a randomly
selected matched gene pair was chosen. Significant genes from in vitro human cells under different
treatment conditions and in vivo mouse lung and blood were matched and identified.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/11/
2635/s1. Table S1. contains the name, tissue fold change, cell fold change, and disease implications of all mRNAs
identified by the concordance study.
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